ID
12246
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072
Keywords
Versions (3)
- 10/1/15 10/1/15 -
- 10/28/15 10/28/15 -
- 10/28/15 10/28/15 -
Uploaded on
October 28, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Pharmacokinetics BO17072 NCT00090051
Pharmacokinetics Cycle 1 and 3 of Chronic lymphocytic leukemia NCT0090051
Description
If patient takes Rituximab on day 1, then start of Fludarabine and Cyclophosphamide pharmacokinetic sampling starts on day 2, immediately prior the infusion.
Description
After the end of infusion
Data type
time
Measurement units
- h
Alias
- UMLS CUI [1]
- C0040223
Description
Sampling number
Data type
integer
Alias
- UMLS CUI [1]
- C1299222
Description
Sample collection date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C1549498
Description
Sample collection time
Data type
time
Measurement units
- hh:mm
Alias
- UMLS CUI [1]
- C0427352
Description
Remarks
Data type
text
Alias
- UMLS CUI [1]
- C0947611